Table 3.
Controlled recurrent biliary obstruction studies
|
Ref.
|
Number of patients
|
Etiology
|
Type of study design
|
Case control analysis
|
Method
|
RFA device
|
Aim
|
Results
|
| Sharaiha et al[27] | 66 (26 RFA) | CCC (n = 37) PC (n = 29) | Retrospective case control study | Yes | ERFA before stenting (26pts) vs stenting alone (40 pts) | Habib EndoHPB | Survival; Stent patency; Adverse events (AE) | (1) The median survival was 5.9 mo in both groups; (2) SEMS patency rates were equivalent; (3) No differences in AE (2 RFA vs 3 no-RFA) |
| Strand et al[29] | 48 (16 RFA) | CCC | Retrospective case control study | Yes | ERFA (16 pts) vs PDT (32) | Habib EndoHPB | Survival, stent occlusion | (1) Median survival of 9.6 mo in RFA vs 7.5 mo in PDT group; (2) RFA group more frequent stent occlusion (0.06 vs 0.02, P = 0.008) and cholangitis (0.13 vs 0.05, P = 0.008) |
| Kallis et al[35] | 69 (23 RFA) | PC | Retrospective case control study | Yes | ERFA before stenting (23 pts) vs stenting alone (46 pts) | Habib EndoHPB | Survival, stent patency | (1) Survival time in RFA group 226 vs 123.5 da in controls (P < 0.01); (2) SEMS patency rate equivalent in both group |
| Liang et al[31] | 76 (34 RFA) | CCC | Retrospective case control study | Yes | ERFA before stenting (34 pts) vs stenting alone (42 pts) | Habib EndoHPB | Survival, stent patency, adverse events | (1) The median survival in the ERFA + SEMS group was significantly better vs SEMS only (P = 0.036); (2) ERFA+ SEMS patency rate 9.5 mo vs 8.4 mo; (P = 0.024); (3) AE equivalent |
| Sampath et al[51] | 25 (10 RFA) | CCC | Retrospective case control study | Yes | ERFA before stenting (10 pts) vs stenting alone (15 pts) | Habib EndoHPB | Survival | (1) Median survival 404 d vs 228 d in controls. (P < 0.001) |
| Schmidt et al[30] | 34 (14 RFA) | CCC | Retrospective case control study | Yes | Repeated ERFA (14 pts) vs repeated PDT (20) | Habib EndoHPB | Bilirubin levem Advere events, | (1) PDT group no significant decrease (P = 0.67) vs in RFA significant decrease (P = 0.046); (2) AE more frequently in PDT (n = 8; 40%) than with RFA (n=3; 14.21%) (P = 0.277). |
| Bokemayer et al[33] | 54 (32 RFA) | CCC (n = 45 + 1 intrahepatic); PC (n = 2); GB (n = 2); Other (n = 4) | Retrospective case control study | Yes | ERFA before stenting (32 pts) vs stenting alone (22 pts) | Habib EndoHPB | Survival | (1) Survival time in RFA group 342 ± 57 vs 221 ± 26 d in controls; (P = 0.046) |
| Yang et al[32] | 65 (32 RFA) | CC | Randomised controlled trial | Yes | ERFA before stenting (32 pts) vs stenting alone (33 pts) | Habib EndoHPB | Overall survival, stent patency; post-ERCP AE | (1) ERFA + stent vs the stent only (13.2 ± 0.6 vs 8.3 ± 0.5 mo, P < 0.001); (2) Stent patency (6.8 vs 3.4 mo, P = 0.02); (3) Similar AE 6.3% vs 9.1%, (P = 0.67) |
RFA: Recurrent biliary obstruction; CCC: Cholangiocarcinoma; PC: Pancreatic cancer; GB: Gallbladder cancer; pts: Patients; AE: Adverse events; SEMS: Self-expandable metal stents.